NICE approves aripiprazole in adolescents

Aripiprazole is also licensed for the treatment of manic episodes in bipolar disorder.
Aripiprazole is also licensed for the treatment of manic episodes in bipolar disorder.

Aripiprazole (Abilify) has been accepted for second-line NHS use in adolescents.

The atypical antipsychotic is recommended as an option for the treatment of schizophrenia in patients aged 15–17 years in whom risperidone is contraindicated, not tolerated or does not provide adequate symptom control.

NICE recommended aripiprazole in these circumstances because its efficacy and price are comparable to those of other alternatives to risperidone available on the NHS, but it is less likely to cause weight gain – a particularly troublesome side-effect for adolescents.

Use of aripiprazole in adults with schizophrenia (18 years and older) was not considered in the appraisal. The NICE clinical guideline on schizophrenia covers the management of schizophrenia in this age group.

View Abilify drug record

NICE guidance on aripiprazole

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases